Singapore-based Prestige BioPharma and Hyderabad-based Dr. Reddy’s have entered into an exclusive partnership for the supply and commercialization of Prestige's a proposed biosimilar to Roche’s Herceptin in select countries in Latin America and Southeast Asia.
The deal surrounds Prestige's lead biosimilar, trastuzumab (HD201) that can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer. The partnership will leverage Prestige's biosimilar development and manufacturing expertise and Dr. Reddy's commercial market prowess — Prestige will manufacture a commercial supply of HD201 from its manufacturing facilities in Osong, South Korea and Dr. Reddy’s will handle local registrations, marketing and sales in the licensed territories.
Just last week, Prestige announced the grand opening of its global-scale Vaccine Centre in Osong, South Korea, where it will focus on two COVID-19 vaccine projects to produce Sputink V and Sputink Light vaccines.
